الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 228 |  |  |
| | | from | 228 | | |
Abstract
The systemic availability of curcumin is very low after oral administration; this limits their therapeutic potential. This study aims to increase the bioavailability of curcumin; the highest reproducible solubility modality will be applied on an experimental carcinogenesis models in order to evaluate its chemo-preventive, chemotherapeutic effects and antitumor potential. Animals were divided into: group I “Control group”, group II “Positive control group”, group III “Therapeutic group”, and group IV “Preventive group”. Colorimetric assays, flowcytometric assay, immunohistochemistry assay, and chromosomal aberration assay were performed to detect the anti-oxidants, and anti-apoptotic markers. We found that administrating of curcumin (200 mg/kg I.P. bound to 5% BSA in PBS, pH 7.4) results in a significant inhibitory effect on tumor in vivo. An anti-oxidant effect and anti-tumor effect of curcumin in vivo was observed. A significant reduction in anti-oxidants and tumor markers levels in tumor treated animals when compared with untreated ones. As well as, apoptotic effect of curcumin was observed in the increasement of caspase-3 activity and the reduction of Bcl-2 expression. Conclusion: curcumin bound BSA has a strong inhibitory activity against tumors. The results of clinical trials will be needed to spur the development of curcumin as cancer preventive and therapeutic.